Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm underlain by the formation of BCR-ABL1 -an aberrant tyrosine kinase -in the leukaemic blasts. Long-term survival rates in CML prior to the advent of tyrosine kinase inhibitors (TKIs) were dismal, albeit the incidence of secondary malignancies was higher than that of age-matched population. Current figures confirm the safety of TKIs with conflicting data concerning the increased risk of secondary tumours. We postulate that care has to be taken when distinguishing between coexisting, secondary-to-treatment and second in sequence, but independent tumourigenic events, in order to achieve an unbiased picture of the adverse effects of novel treatments. To illustrate this point, we present a case of a patient in which CML and peripheral T-cell lymphoma (PTCL) coexisted, although the clinical presentation of the latter followed the achievement of major molecular response of CML to TKIs.
1
). Most patients are diagnosed in the chronic phase (CP) characterised by hepatosplenomegaly, thrombocytosis, and increased white blood count (WBC) made up of mature granulocytes and their precursors (reviewed in 1 ) . Until relatively recently, the natural disease history evolved from the CP -usually lasting several years -to the ultimately fatal accelerated (AP) and blast (BP) phases. The development of the TK inhibitors (TKIs) has allowed for the achievement of major molecular response (MMR) and long-term disease control 2 . A small percentage (< 5%) of cases treated with TKIs for CML develops second cancer 3 . These include mostly skin comprising melanoma, prostate and gut tumours 3, 4 . Second haematological tumours in these series of patients are rare albeit exist 3, 4 . On the other hand, cases of concurrent CML plus another haematological disorder (or even two 5 ), such as myeloma or B-cell non-Hodgkin lymphoma (NHL), have been reported 6, 7 (and references therein). An exact distinction between a secondary and coexisting malignancy may prove problematic. Here we report a case of CML diagnosed in CP, in which the treatment with imatinib led to the disclosure of lymphocytosis, later identified as peripheral T-cell lymphoma (PTCL).
/L, Fig. 1A ). At 10 months, lymphocytosis worsened despite the achievement of major molecular response (MMR; PB BCR-ABL1/ABL1 ratio 0.02%; Fig. 1A ) and further investigations revealed clonal expansion of karyotypically (Fig. 1B) and phenotypically (Fig. 1C) aberrant T-cells in PB and, later, in BM. Furthermore, monoclonal gamma-T-cell receptor gene rearrangement was detected in BM-derived DNA by PCR and low-level (10%) CD34-negative T-cell infiltration was found in BM whilst total body CT scan showed generalised lymphadenopathy. These findings together with histological examination of lymph node biopsy prompted the diagnosis of PTCL, not otherwise specified (NOS), and appropriate treatment commenced. First (CHOP-like chemotherapy) and second (IGEV poly-chemotherapy) line therapies failed. Instead, complete haematological and cytogenetic response of lymphoma was reached following the third line approach i.e. immunochemotherapy (Campath monoclonal antibody plus gemcitabine). During lymphoma treatment, imatinib was put on hold due to therapy/lymphoma-related myelosuppression without a negative effect on MMR of the CML. Considering the availability of a familial donor and refractory PTCL, the patient underwent a PB stem cell transplant (PBSCT). Donor granulocyte engraftment and complete remission of both haematological diseases lasted for six months after the procedure. Thereafter, progressive engraftment failure and the expansion of recipient haematopoiesis followed. The patient died at 11 months from PBSCT due to respiratory failure. Figure 1A summarises the clinical and treatment history of the patient.
Results
The BCR-ABL1 protein found in the patient was of the p210 type and the breakpoints were ascertained by PCR with primers BCR-b1-A and ABL-a3-B (all primer sequences are given in Table 1 ). The finding of an amplicon of 417bp identified the transcript as b3-a2. Conventional cytogenetic analysis, performed at presentation of the second malignancy, has disclosed the presence of a t(X;14)(q28;q11) in the lymphoma cells. This translocation has been previously described to result in the breakage of the BRCC3 gene and its fusion to the T-cell receptor alpha or delta (TCRA/D) locus on chromosome 14. We confirmed by PCR amplification and subsequent sequencing the involvement of the two loci. Next, in order to track the origins of the lymphoma, we designed primers (primers X;14_F1, X;14_R1) mapping up and down-stream of the fusion junction and applied them to cDNA retrotranscribed from mRNA sample extracted at the time of CML diagnosis. The end point-qualitative PCR experiments showed that the transcript deriving from the t(X;14) translocation fusion was present at the time of the first diagnosis ( Fig. 2A, top panel) . In parallel, we have looked for the BCR-ABL1 fusion in mRNA deriving from PB sample taken at the time of PTLC diagnosis and found BCR-ABL1 transcript in it ( Fig. 2A , bottom panel) although at very low levels (primers BCR-b1-A and ABL-a3-B). The specificity of the faint band seen in the lane corresponding to the PTCL diagnostic sample was confirmed in a nested PCR protocol (primers BCR-b2-C and ABL-a3-D). Thus, we quantified the transcripts of the two translocations by qRT-PCR using two primer pairs for each fusion (qBCR_F1, qABL_R1, qBCR_F2, qABL_R2, X;14_F1, X;14_R1, X;14_F2, X;14_R2) and the SybrGreen methodology on both diagnostic samples and found that the expression level of the t(X;14) product in the diagnostic CML sample was about 4% of the expression of the BCR-ABL1 fusion transcript in the same sample, whereas the expression of BCR-ABL1 in the diagnostic PTCL sample was more than 10 times less (Fig. 2B) . Next, we enumerated the reciprocal tumour burden in the two diagnostic samples by performing interphase FISH on archival methanol/acetic acid-fixed bone marrow samples taken at the times of CML and PTCL diagnoses. We used commercial probes designed to detect the presence of BCR/ABL fusion or TCRA/D locus breakage on the chromosome 14 caused by the t(X;14) formation. The experiments with the Vysis LSI BCR/ABL DC/DF probe (Abbott Molecular Inc., Des Plaines, IL, USA) disclosed the presence of an atypical hybridisation pattern consisting of one fusion signal, two green and one red signal (Fig. 3a) . Such pattern has previously been reported and corresponds to a microdeletion of the reciprocal ABL locus. Cells with BCR/ABL fusion signal constituted 82% of the nuclei scored in the diagnostic CML sample. Not a single BCR/ABL+ cell was seen in the diagnostic PCTL sample when scoring a 1000 cells. FISH experiments with the use of TCRA/D Break-apart probe (Cytocell, Cambridge, UK) showed that the diagnostic CML sample contained about 4.6% (48/1028) of cells with the rearrangement in the TCRA/D locus (Fig. 3B) , whilst at the time of PTCL diagnosis the percentage of such cells increased to 83%. We next applied the two probes together 
the TCRA/D Break-apart ones (600 kb vs ~150 kb). Cells with BCR/ABL fusion and no TCRA/D rearrangement as well as cells with TCRA/D split and no BCR/ ABL fusion were identified in percentages equal to the ones seen for single-probe experiments. No cells with both abnormalities were encountered in the diagnostic CML sample (Fig. 3C) .
Discussion
Second malignancies diagnosed in patients previously treated for cancer can represent de novo unrelated oncogenic processes or be related/induced by the treatment received. Advances in diagnostics as well as in curative and supportive therapy have increased the number of long-term cancer survivors that may be prone to the development of secondary tumours arising from normal tissue exposure to the damaging effects of ionizing radiation or genotoxic stress of chemotherapy [8] [9] [10] [11] . Recently, reports are emerging of additional secondary premalignant and malignant events, including RAS-mutant leukaemia, in melanoma patients on BRAF-inhibitors 12 . In particular, the patterns of incidence and latency of secondary lymphomas are distinct from that of myeloid malignancies and solid cancers. Indeed, the risk of secondary lymphomas increases after the first 5 years of completion of chemotherapy or radiotherapy and persists for more than three decades 13 . The lymphocytosis observed in our patient as soon as 3 months since the beginning of treatment with imatinib did not follow this pattern and prompted us to study the temporal relationship between the two malignancies. Interestingly, the occurrence of mono-/oligoclonal T-cell-or NK-cell-large granular lymphocyte lymphocytosis has been reported in a proportion of patients treated with dasatinib and to a lesser extent in those treated with imatinib 14 . In order to answer the question of whether the two diseases manifested in the case presented here were genetically related or a coincidence, we took advantage of the presence of disease-specific translocations as clonal markers and looked for the presence of sequences derived from the respective fusions in the reciprocal diagnostic samples. The end point-qualitative PCR experiments showed that the transcript deriving from the t(X;14)(q28;q11) translocation fusion was already present at the time of the first diagnosis suggesting that a small clone of lymphoma cells existed 10 months before the finding of an overt lymphoma or that a small subclone of BCR-ABL1 bearing cells existed in which t(X;14) was also present. However, FISH experiments confirmed that there were no cells in which the two translocations co-existed, i.e. PTCL cells are BCR/ABL negative. This is inconsistent with the theory of a subclone of CML evolving into PTCL as one would expect that such clonal evolution resulted in a cell that continued to bear t(9;22) and express BCR-ABL1. There is a slight discrepancy between the results of qPCR and FISH data when it comes to the evaluation of the CML burden at the time of PTCL diagnosis. The explanation for it includes several issues -the transcript levels/cell and the efficiency of PCR for the two primer pairs may be different in the two clones, the C t s were high and therefore outside of the range of accurate quantification. Nonetheless, there is no doubt as to the presence of residual BCR-ABL1 transcript at the time of PTCL diagnosis, as diagnostic and nested protocols showed its presence.
The novelty of the case described here lies also in the finding of the t(X;14)(q28;q11) translocation in PTCL. This translocation, together with the more frequent inversion of the chromosome 14, has been previously described in T-cell prolymphocytic leukaemia 15 , admittedly, a disease from within the same spectrum of lymphoproliferations. PTCL NOS constitutes a rare and aggressive tumour whose molecular pathogenesis is still challenging 16 , albeit shedding light on the tumourigenesis of this disease entity is beyond the scope of this report.
Although secondary tumours have been described after imatinib therapy, the analyses of their frequency with respect to the age-adjusted general population yielded conflicting results 3, 4, [17] [18] [19] . Differences in cohort size, follow-up time and the interpretation of the term "secondary cancer" may have been responsible for this difference. Moreover, many of the above mentioned studies analysed historical data from cancer registries selecting patients treated with diverse modalities over variable periods of time. Clearly, working with historical data, especially if old, gives no opportunity of reviewing and confirming the diagnosis, anamnesis and so on. In the most recent article on the incidence of second malignancies following treatment with TKIs, Gunnarsson et al. 19 reported an increased risk of a second cancer for the population of CML sufferers, indicating that such risk may more likely be related to the CML itself and not to the therapy with imatinib or other inhibitors. Without doubt, TKIs have dramatically changed the prognosis of patients with CML and are considered safe, well tolerated and non-mutagenic 2 . Our study suggests that in some cases the second malignancy is not secondary to TKIs treatment but instead was present at the time of diagnosis of CML. In such cases, the eradication of CML with the use of TKIs may create an opportunity for the lymphoma to develop overtly. We underline the importance of investigating the possibility that the second cancer in the context of a previous CML diagnosis was pre-or co-existent.
Methods
We obtained informed consent from the patient prior to sample collection. The ipsogen BCR-ABL1 Mbcr IS-MMR Kit (Qiagen, Hilden, Germany) was used according to manufacturer's instructions. Immunophenotypic/cytogenetic analyses of CML and PTCL were performed following standard diagnostic procedures and were carried out in accordance with the guidelines approved by Ethics Committee of the Istituto Europeo di Oncologia, Milan, Italy. Primers listed in Table 1 were used for molecular characterisation of breakpoints and specific transcript detection. Standard PCR reactions were performed 
